Outcomes of rare patients with a primary cutaneous CD30+ lymphoproliferative disorder developing extracutaneous disease-Reference-Cited by-同舟云学术

Outcomes of rare patients with a primary cutaneous CD30+ lymphoproliferative disorder developing extracutaneous disease

Published:2020-03-05 Issue:10 Volume:135 Page:769-773
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Melchers Rutger C.¹^ORCID,Willemze Rein¹,Vermaat Joost S. P.²,Jansen Patty M.³,Daniëls Laurien A.⁴,Putter Hein⁵,Bekkenk Marcel W.⁶,de Haas Ellen R. M.⁷,Horvath Barbara⁸,van Rossum Michelle M.⁹,Sanders Cornelus J. G.¹⁰,Veraart Joep C. J. M.¹¹,Vermeer Maarten H.¹^ORCID,Quint Koen D.¹

Affiliation:

1. Department of Dermatology,

2. Department of Haematology,

3. Department of Pathology,

4. Department of Radiotherapy, and

5. Department of Biomedical Data Sciences, Leiden University Medical Centre, Leiden, The Netherlands;

6. Department of Dermatology, Academic Medical Centre and Vrije University Medical Centre, Amsterdam, The Netherlands;

7. Department of Dermatology, Erasmus Medical Centre, Rotterdam, The Netherlands;

8. Department of Dermatology, University Medical Centre Groningen, Groningen, The Netherlands;

9. Department of Dermatology, Radboud University Medical Centre, Nijmegen, The Netherlands;

10. Department of Dermatology, University Medical Centre Utrecht, Utrecht, The Netherlands; and

11. Department of Dermatology, Maastricht University Medical Centre, The Netherlands

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/135/10/769/1717851/bloodbld2019002799.pdf

Reference25 articles.

1. WHO-EORTC classification for cutaneous lymphomas;Willemze;Blood,2005

2. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas;Willemze;Blood,2019

3. Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment;Bekkenk;Blood,2000

4. Lymphomatoid papulosis: treatment response and associated lymphomas in a study of 180 patients;Wieser;J Am Acad Dermatol,2016

5. Frequency and risk factors for associated lymphomas in patients with lymphomatoid papulosis;Cordel;Oncologist,2016

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Brentuximab-vedotin in combination with cyclophosphamide, doxorubicin, prednisolone for the treatment of aggressive CD30-positive cutaneous T-cell lymphomas;Leukemia & Lymphoma;2023-05-31

2. CD30‐positive lymphoproliferative disorders—An Australian Clinical Practice Statement from the Peter MacCallum Cancer Centre;Australasian Journal of Dermatology;2023-03-09

3. Diagnosis and management of cutaneous lymphomas and lymphoid proliferations in children, adolescents and young adults (CAYA);Best Practice & Research Clinical Haematology;2023-03

4. Genetic and epigenetic insights into cutaneous T-cell lymphoma;Blood;2022-01-06

5. Oncogenic Mutations and Gene Fusions in CD30-Positive Lymphoproliferations and Clonally Related Mycosis Fungoides Occurring in the Same Patients;JID Innovations;2021-09